Astal Laboratories Limited , a pharmaceutical company, recently conducted an Extraordinary General Meeting (EGM) to address significant corporate actions. The meeting, held on November 6, 2025, via video conferencing, saw the participation of 24 members and focused on three key agenda items that could potentially reshape the company's future.

Key Highlights of the EGM

1. Increase in Authorized Share Capital: The company proposed to increase its authorized share capital and alter the capital clause of the Memorandum of Association accordingly.

2. Acquisition of Sriven Pharmachem: Astal Laboratories sought approval for acquiring a 100% stake in Sriven Pharmachem India Private Limited through an equity share swap via preferential allotment.

3. Approval of Related Party Transaction: The meeting addressed the approval of a material related party transaction for the acquisition of Sriven Pharmachem shares.

Meeting Details and Proceedings

The EGM was conducted through video conferencing, adhering to modern corporate governance practices. Dr. Radhakishore Pandrangi chaired the meeting, which began at 3:00 PM IST and concluded at 3:21 PM IST.

Key Attendees:

Voting Process and Resolutions

All resolutions were conducted through e-voting on the Central Depository Services (India) Limited (CDSL) platform. The company appointed Mr. Mahendra Prakash Khandelwal, a Practicing Company Secretary, as the scrutinizer for the e-voting process.

Resolutions Presented:

1. Increase in Authorized Share Capital (Ordinary Resolution)
2. Acquisition of Sriven Pharmachem India Private Limited (Special Resolution)
3. Approval of Material Related Party Transaction (Ordinary Resolution)

The company secretary, Mr. Mahendra Kumar, informed that the consolidated voting results would be disseminated to the stock exchange and made available on the company's website within 48 hours of the meeting's conclusion.

Implications and Next Steps

The outcomes of these resolutions could significantly impact Astal Laboratories' financial structure and market position. The proposed acquisition of Sriven Pharmachem, if approved, may expand the company's product portfolio and market reach. Meanwhile, the increase in authorized share capital could provide the company with more flexibility for future growth initiatives.

Investors and stakeholders are advised to keep an eye on the voting results and subsequent announcements from the company for a clearer picture of Astal Laboratories' strategic direction in the coming months.

As the pharmaceutical sector continues to evolve, such corporate actions may reflect Astal Laboratories' efforts to strengthen its position in the market and create value for its shareholders.

Astal Laboratories Limited has announced a crucial board meeting scheduled for October 9, 2025, to deliberate on several significant matters that could shape the company's future trajectory.

Key Agenda Items

The board of directors will convene to discuss and potentially approve the following key items:

Authorized Share Capital Increase

The company is considering an increase in its authorized share capital, subject to regulatory and shareholder approvals.

Preferential Issue of Equity Shares/Convertible Warrants

The board will evaluate the issuance of equity shares or convertible warrants on a preferential basis, in accordance with the Companies Act, 2013, and SEBI regulations.

Acquisition Decision

A final decision is expected regarding the acquisition of 100% equity shares of Sriven Pharmachem India Private Limited (SPIPL).

Extraordinary General Meeting (EGM) Preparations

The board will review and approve the draft notice for an EGM, set the date and venue, and appoint a scrutinizer for the e-voting process.

Trading Window Closure

In compliance with SEBI regulations and the company's insider trading policy, Astal Laboratories has implemented a trading window closure. This restriction applies to all directors, officers, designated persons, and their immediate relatives, effective from October 1, 2025, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2025.

Corporate Governance Measures

The company has taken steps to ensure transparency and compliance:

• The board meeting will be held at the corporate office in Telangana.
• A scrutinizer will be appointed to oversee the e-voting process for the upcoming EGM.
• The company secretary, Mahendra Kumar, has officially communicated these developments to the BSE.

Investors and stakeholders of Astal Laboratories will be keenly watching the outcomes of this board meeting, as the decisions made could significantly impact the company's capital structure, expansion plans, and future growth prospects.

Note: All dates mentioned in this article are based on future projections as stated in the company's announcement.